This patent teaches how to induce endogenous islet stem cells to multiply through administration of gastrin together with a ligand of the EGF receptor such as TGF alpha. One of the principles behind the current company doing clinical trials with this, Dr Tony Cruz, is also involved in the company Stem Cell Therapeutics, which is performing clinical trials with exogenous agents that stimulate endogenous neural stem cells for the treatment of stroke.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.